Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management.

Related Articles

Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 May 3;

Authors: Nicolatou-Galitis O, Nikolaidi A, Athanassiadis I, Papadopoulou E, Sonis S

Abstract
OBJECTIVE: We report the clinical features and management outcomes in 7 patients with everolimus-related stomatitis. STUDY DESIGN: Fifteen women with hormone-receptor-positive advanced breast cancer receiving everolimus combined with exemestane were prospectively evaluated to assess the development of stomatitis. Oral ulcers were diagnosed based on established criteria. RESULTS: Seven patients developed stomatitis (46.6%). All patients were treated with topical dexamethasone solution, while everolimus was temporarily discontinued in 4 patients. Stomatitis resolved within 1-2 weeks. Two of the 4 patients, who had interrupted everolimus, developed recurrent stomatitis following drug resume and everolimus was again discontinued and restarted after 2 weeks. To date, 5 patients receive everolimus in full dose. The 2 patients, who developed recurrent stomatitis, received a reduced dose. CONCLUSIONS: Everolimus-related oral ulcers were frequent and led to dose modifications. Controlled trials, endorsing a consensus in terminology, are needed to evaluate measures on prevention and management of this unique toxicity.

PMID: 23643584 [PubMed - as supplied by publisher]

supplier Dalcetrapib selleckchem Dalcetrapib ic50 selleck chemicals Dalcetrapib solubility selleck chemicals